Jeanine M. D'Armiento, MD, PhD

Board Certifications: 
Pulmonary Disease Medicine, Internal Medicine
Accepting New Patients
Profile Hero

Overview

Areas of Expertise / Conditions Treated

Lung Disease, Vascular Disease, Pulmonology

Academic Appointments

  • Assistant Professor of Medicine (in Anesthesiology)

Administrative Titles

  • Associate Dean for Gender Equity and Career Development

We are dedicated to the comprehensive evaluation of patients with lymphangioleiomyomatosis and other lung diseases in parallel with a commitment to basic research and application of principles to the therapeutic aspects of lung disease.

Jeanine D’Armiento, M.D, Ph.D. has been caring for patients with LAM for over ten years. She received her M.D. and Ph.D. from UMDNJ-Robert Wood Johnson, and completed Internal Medicine residency and Pulmonary fellowship at Columbia University Medical Center.

Her research focus in LAM centers on the role of HMGA2 in disease pathogenesis. She has been performing pulmonary research for more than 15 years, with interests in LAM, emphysema, and lung injury and repair.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Schedule an Appointment

Phone Appointments

New and Existing Patients:
212-305-7114

Location(s)

ColumbiaDoctors Columbus Circle
1790 Broadway
New York, NY 10019
Primary

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • UMDNJ/Robert Wood Johnson Medical School
  • Internship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Board Certifications

  • Pulmonary Disease Medicine
  • Internal Medicine

Honors & Awards

  • 1985 Henry Rutgers Scholar Honors
  • 1993 Research Award for Trainees, National Institutes of Health
  • 1996 Burroughs Welcome Career Award
  • 1997 Dewitt S. Goodman Fellowship
  • 2000 UMDNJ Distinguished Alumni Award
  • 2003 American Society of Clinical Investigation
  • 2007-2012 Established Investigator Award-American Heart Association

Research

We are a multi-disciplinary center focusing on the care of patients with LAM and other rare lung diseases. In addition to the care of patients with LAM, we conduct both clinical and basic science research focusing on this disease.

The research in our laboratory centers on several projects directed at understanding the role of matrix metalloproteinases in tissue destruction during disease processes. Our laboratory has made use of transgenic mice in which to express these enzymes at pathophysiological levels in specific tissues so as to recreate the natural proteolytic imbalance. Through the generation of these transgenic animals we have been able to develop several mouse models of emphysema, atherosclerosis and heart failure and also gain insight into the role these enzymes may be playing in the pathogenesis of these diseases.

Several years ago we demonstrated that transgenic mice which express human MMP-1 (matrix metalloproteinase 1, interstitial collagenase) in the lung develop emphysema. We have recently demonstrated that human patients with emphysema express MMP-1 within their lung parenchyma and normal patients do not. In this study it was found that the type II pneumocyte of the lung of patients with emphysema expressed MMP-1. Therefore, we are proceeding with in vitro studies to determine the mechanism by which MMP-1 is induced in the type II pneumocyte. In our preliminary work we have found that cigarette smoke extract can induce MMP-1 expression in lung epithelial cells and this occurs through activation of the MAP Kinase signaling pathway. Through in vitro promoter studies we have identified the region of the MMP-1 promoter that responds to cigarette smoke.

These studies demonstrate that cigarette smoke induced changes on the epithelial cell of the lung from patients with emphysema may be critical in disease pathogenesis. Our future studies will attempt to identify the molecular pathway leading to up regulation of MMP-1 and other genes in the emphysema lung and possibly provide us with alternative drug targets for this disease. 

Research Interests

  • The major goal of our research program is to develop insight into lung physiology and pathology through understanding the mechanisms altering lung injury and repair and translating these findings into practical clinical solutions

Grants

Smoke Induced Airway Injury in COPD
Grant Agency: NIH – R01 HL086936
PI: Jeanine D’Armiento, M.D., Ph.D.

Inducible Macrophage Specific Gene Expression in Diseases
Grant Agency: NIH – ARRA-Challenge Grant RC HL100384
PI: Jeanine D’Armiento, M.D., Ph.D.

Novel Mechanisms of MMP Induction in Vascular Smooth Muscle Cells
Grant Agency: American Heart Association – Established Investigator Award
PI: Jeanine D’Armiento, M.D., Ph.D.

Allosteric Modulation of Cardiovascular Ion Channels
Grant Agency: NIH – P01 HL086936
PI: Arthur Karlin, Ph.D., PI
Role: Director of Core

Molecular Basis of Sudden Cardiac Death
Grant Agency: NIH – P01 HL67849
PI: Andrew Marks, M.D.
Role: Director of Core 

The Role of MMP-13 in Emphysema Development
Grant Agency: Flight Attendant Medical Research Institute
PI: Monica Goldklang, M.D.
Role: Sponsor 

Stony Wold: Training Fellowship
Grant Agency: Stony Wold-Herbert Fund, Inc.
PI: Monica Goldklang, M.D.
Role: Sponsor 

IN VIVO IMAGING OF LUNG APOPTOSIS IN ALPHA-1 ANTITRYPSIN DEFICIENCY (Private)

Jul 1 2017 - Jun 30 2019

IN VIVO IMAGING OF DESTRUCTIVE PROCESSES IN COPD (Federal Gov)

Sep 19 2016 - Jun 30 2019

THE ROLE OF NEURAL CREST STEM CELLS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) (Private)

Aug 1 2017 - Jul 31 2018

TARGETING CHOLESTEROL TRANSPORT AS A NOVEL THERAPY IN EMPHYSEMA (Private)

Jul 1 2017 - Jun 30 2018

SMOKE INDUCED AIRWAY INJURY IN THE LUNG (Federal Gov)

Feb 19 2007 - Jun 30 2018

LAM FOUNDATION- MIDAS SITE AGREEMENT (Federal Gov)

Aug 1 2016 - Jul 31 2017

IMPLICATIONS OF MMP-13 MEDIATED CLEAVAGE OF ALPHA-1 ANTITRYPSIN (Private)

Jul 1 2015 - Jun 30 2017

EFFECT OF SMOKE EXPOSURE IN ALPHA1 ANTITRYPSIN MOUSE MODEL (Private)

Jul 1 2015 - Jun 30 2017

TARGETING MATRIX METALLOPROTEINASES TO LIMIT IMUNOPATHOLOGY IN AIRBORNE INFECTION (Federal Gov)

Jul 18 2014 - Jun 30 2017

LAM PILOT STUDY WITH IMATINIB MESYLATE (LAMP-1) (Federal Gov)

Sep 30 2014 - Sep 29 2016

IMAGING RAGE PRO-INFLAMMATORY SIGNALING AND CELLULAR APOPTOSIS IN EMPHYSEMA (Federal Gov)

Sep 25 2012 - Jun 30 2015

CIGARETTE SMOKE REGULATION OF CHOLESTEROL TRANSPORT IN ATHEROSCLEROSIS (Private)

Jun 2 2014 - Aug 10 2014

THE ROLE OF MMP-13 IN EMPHYSEMA DEVELOPMENT (Private)

Jul 1 2011 - Jun 30 2013

NOVEL MECHANISMS OF MMP INDUCTION IN VASCULAR SMOOTH MUSCLE CELLS (Private)

Jan 1 2008 - Dec 31 2012

INDUCIBLE MACROPHAGE SPECIFIC GENE EXPRESSION IN DISEASES (Federal Gov)

Sep 30 2009 - Aug 31 2012

THE ROLE OF MMP-13 IN EMPHYSEMA DEVELOPMENT (Private)

Jul 1 2011 - Jun 30 2012

CAREER TRACKS TOWARDS EXCELLENCE (Private)

Jul 1 1993 - Jun 30 2012

USE OF A MMP-1 INHIBITOR IN A RABBIT MODEL OF SMOKE-INDUCED EMPHYSEMA (Private)

Jan 1 2011 - Dec 31 2011

CIGARETTE SMOKE AND CELL SIGNALING IN EMPHYSEMA (Private)

May 1 2003 - Apr 30 2005